The article describes the development and validation of a CRISPR-Cas12-based lateral flow assay (DETECTR) for rapid detection of SARS-CoV-2 from respiratory swab RNA extracts. The DETECTR assay combines reverse transcription and isothermal amplification using loop-mediated isothermal amplification (RT-LAMP) with Cas12 detection. The assay was designed to target the E and N genes of SARS-CoV-2 and was validated using contrived reference samples and clinical samples from patients with COVID-19 and other viral respiratory infections. The DETECTR assay provides a visual and faster alternative to the US Centers for Disease Control and Prevention's SARS-CoV-2 real-time RT-PCR assay, with 95% positive predictive agreement and 100% negative predictive agreement. The assay has a rapid turnaround time of approximately 30-40 minutes and can be run using routine protocols and commercially available reagents, making it a promising tool for rapid and accessible diagnostic testing of SARS-CoV-2.The article describes the development and validation of a CRISPR-Cas12-based lateral flow assay (DETECTR) for rapid detection of SARS-CoV-2 from respiratory swab RNA extracts. The DETECTR assay combines reverse transcription and isothermal amplification using loop-mediated isothermal amplification (RT-LAMP) with Cas12 detection. The assay was designed to target the E and N genes of SARS-CoV-2 and was validated using contrived reference samples and clinical samples from patients with COVID-19 and other viral respiratory infections. The DETECTR assay provides a visual and faster alternative to the US Centers for Disease Control and Prevention's SARS-CoV-2 real-time RT-PCR assay, with 95% positive predictive agreement and 100% negative predictive agreement. The assay has a rapid turnaround time of approximately 30-40 minutes and can be run using routine protocols and commercially available reagents, making it a promising tool for rapid and accessible diagnostic testing of SARS-CoV-2.